Gilead to buy 49.9% stake in cancer drug developer Pionyr for $275 million - Reuters
6:12am PDT - June 23rd, 2020 remdesivir - ReutersGilead Sciences Inc said on Tuesday it would buy a 49.9% stake in privately held cancer immunotherapies developer Pionyr Immunotherapeutics Inc for $275 million.